These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22380407

  • 1. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G, Mallick S, Sharma V, Joshi N, Purkait S, Jha P, Sharma MC, Suri V, Julka PK, Mahapatra AK, Singh M, Kale SS, Sarkar C.
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G, Huang S, Zhang J, Wu Z, Lin S, Wang Y.
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinicopathologic and genomic features of gliosarcomas.
    Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH.
    J Neurooncol; 2012 May; 107(3):643-50. PubMed ID: 22270848
    [Abstract] [Full Text] [Related]

  • 5. O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications.
    Kang SH, Park KJ, Kim CY, Yu MO, Park CK, Park SH, Chung YG.
    J Neurooncol; 2011 Feb; 101(3):477-86. PubMed ID: 20556478
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
    Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G.
    J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
    [Abstract] [Full Text] [Related]

  • 8. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR.
    Neuroimage; 2010 Jan 15; 49(2):1398-405. PubMed ID: 19796694
    [Abstract] [Full Text] [Related]

  • 9. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
    Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.
    J Neurooncol; 2016 Jun 15; 128(2):341-8. PubMed ID: 27025857
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK, Park SH, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW.
    Neuropathology; 2009 Aug 15; 29(4):443-9. PubMed ID: 19170894
    [Abstract] [Full Text] [Related]

  • 15. Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanine-DNA methyltransferase) promoter methylation status.
    Kakkar A, Kumar A, Jha P, Goyal N, Mallick S, Sharma MC, Suri A, Singh M, Kale SS, Julka PK, Sarkar C, Suri V.
    Neuropathology; 2014 Aug 15; 34(4):333-42. PubMed ID: 24521400
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
    Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC.
    Clin Cancer Res; 2009 Nov 01; 15(21):6683-93. PubMed ID: 19861461
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
    Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K.
    Ann Hematol; 2007 Aug 01; 86(8):557-64. PubMed ID: 17508213
    [Abstract] [Full Text] [Related]

  • 19. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E, Tosoni A, Pozzati E, Brandes AA.
    Expert Rev Anticancer Ther; 2008 Nov 01; 8(11):1781-6. PubMed ID: 18983238
    [Abstract] [Full Text] [Related]

  • 20. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K, Watanabe T, Ohta T, Fukushima T, Yoshino A, Ogino A, Katayama Y, Nagase H.
    Int J Oncol; 2008 Sep 01; 33(3):469-75. PubMed ID: 18695875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.